Almirall Adds Novo Nordisk Drug To Dermatology Pipeline
The Spanish drugmaker has licensed an IL-21 inhibitor which has been sitting on the shelf at Novo Nordisk and plans to start Phase II trials soon for as-yet undisclosed dermatological diseases.
The Spanish drugmaker has licensed an IL-21 inhibitor which has been sitting on the shelf at Novo Nordisk and plans to start Phase II trials soon for as-yet undisclosed dermatological diseases.